178 related articles for article (PubMed ID: 15501968)
1. Expression of deltaNp73 predicts poor prognosis in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Morita M; Funa K; Yasumoto K
Clin Cancer Res; 2004 Oct; 10(20):6905-11. PubMed ID: 15501968
[TBL] [Abstract][Full Text] [Related]
2. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
3. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer.
Iwata T; Uramoto H; Sugio K; Fujino Y; Oyama T; Nakata S; Ono K; Morita M; Yasumoto K
Lung Cancer; 2005 Oct; 50(1):67-73. PubMed ID: 15950316
[TBL] [Abstract][Full Text] [Related]
4. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Yoshimastu T; Morita M; Yasumoto K
Lung Cancer; 2005 Jul; 49(1):55-62. PubMed ID: 15949590
[TBL] [Abstract][Full Text] [Related]
5. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
6. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
8. P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
Uramoto H; Sugio K; Oyama T; Hanagiri T; Yasumoto K
Anticancer Res; 2006; 26(2A):983-8. PubMed ID: 16619496
[TBL] [Abstract][Full Text] [Related]
9. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
[TBL] [Abstract][Full Text] [Related]
10. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
11. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
[TBL] [Abstract][Full Text] [Related]
12. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
[TBL] [Abstract][Full Text] [Related]
13. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer.
Kawai H; Ishii A; Washiya K; Konno T; Kon H; Yamaya C; Ono I; Minamiya Y; Ogawa J
Clin Cancer Res; 2005 Jul; 11(14):5084-9. PubMed ID: 16033821
[TBL] [Abstract][Full Text] [Related]
16. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
[TBL] [Abstract][Full Text] [Related]
17. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
19. Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung.
Uchino K; Ito A; Wakayama T; Koma Y; Okada T; Ohbayashi C; Iseki S; Kitamura Y; Tsubota N; Okita Y; Okada M
Cancer; 2003 Sep; 98(5):1002-7. PubMed ID: 12942568
[TBL] [Abstract][Full Text] [Related]
20. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers.
Tammemagi MC; McLaughlin JR; Bull SB
Cancer Epidemiol Biomarkers Prev; 1999 Jul; 8(7):625-34. PubMed ID: 10428201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
